Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a ...

Unlike in the US and New Zealand, where pharma companies can market drugs directly to consumers with certain disclosures, the UK – along with the majority of nations – bans this practice outright.

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those ... Now, he’s a Mets’ batting ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight ... pharmacy benefit managers and how their business practices impact patients. Tens of thousands of Americans will ...

In an effort to curb misuse of opioids and prevent overdose deaths, the College of Physicians and Surgeons of British Columbia released a legally enforceable practice standard, "Safe Prescribing ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...

(Reuters) -Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now she fears a deal struck between CVS Health Corp. and Novo Nordisk A/S ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight ... Now, he’s a Mets’ batting practice pitcher. NewsdayTV’s Carissa Kellman reports. Credit: Newsday/Kendall ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.